Literature DB >> 28652877

Pathology review impacts clinical management of patients with T1-T2 bladder cancer.

Samer L Traboulsi1, Fadi Brimo2, Yutong Yang2, Chelsea Maedler2, Noémie Prévost1, Simon Tanguay1, Armen G Aprikian1, Wassim Kassouf1.   

Abstract

INTRODUCTION: We sought to evaluate the contemporary role of a pathology review on management implications of patients with bladder cancer.
METHODS: A total of 98 consecutive specimens from transurethral resections in patients with suspected bladder tumours were reviewed at our institution by genitourinary pathologist. Patients were classified into risk groups according to pathology reports obtained before and after review. A management course was proposed according to local institutional practice patterns and main urological guidelines.
RESULTS: Overall, 34.7% of pathological reviews had significant changes associated with management implications, the majority of which were due to changes in risk category (and/or stage). On review pathology, 12 patients were recommended radical cystectomy instead of conservative management and two patients avoided radical cystectomy. Six patients initially staged as T1 and whose staging did not change after review had a proposed change in management in the form of early cystectomy as a treatment option, as they were deemed very high-risk secondary to high-risk features (such as carcinoma in situ or lymphovascular invasion found on review). Ten patients initially staged as T2 demonstrated high-risk features on review.
CONCLUSIONS: Review by genitourinary pathologist remains important, as it defines more clearly the tumour risk category and influences the management of T1-T2 bladder cancer patients. A complete initial pathological report has the potential to further decrease the discrepancy between initial and review reports.

Entities:  

Year:  2017        PMID: 28652877      PMCID: PMC5472464          DOI: 10.5489/cuaj.4126

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  22 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

2.  Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital.

Authors:  Rajal B Shah; Jeffrey S Montgomery; James E Montie; Lakshmi P Kunju
Journal:  Urol Oncol       Date:  2012-05-17       Impact factor: 3.498

3.  Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features.

Authors:  Sean R Williamson; Shaobo Zhang; Antonio Lopez-Beltran; Rajal B Shah; Rodolfo Montironi; Puay-Hoon Tan; Mingsheng Wang; Lee Ann Baldridge; Gregory T MacLennan; Liang Cheng
Journal:  Am J Surg Pathol       Date:  2011-04       Impact factor: 6.394

4.  Impact of second opinion pathology in the definitive management of patients with bladder carcinoma.

Authors:  T R Coblentz; S E Mills; D Theodorescu
Journal:  Cancer       Date:  2001-04-01       Impact factor: 6.860

5.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.

Authors:  R Millikan; C Dinney; D Swanson; P Sweeney; J Y Ro; T L Smith; D Williams; C Logothetis
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

6.  The role of pathology review of transurethral bladder tumor resection specimens in the modern era.

Authors:  Michael C Lee; Howard S Levin; J Stephen Jones
Journal:  J Urol       Date:  2010-01-20       Impact factor: 7.450

Review 7.  The impact of variant histology on the outcome of bladder cancer treated with curative intent.

Authors:  Peter C Black; Gordon A Brown; Colin P N Dinney
Journal:  Urol Oncol       Date:  2008-01-14       Impact factor: 3.498

Review 8.  A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens.

Authors:  Donna E Hansel; Mahul B Amin; Eva Comperat; Richard J Cote; Ruth Knüchel; Rodolfo Montironi; Victor E Reuter; Mark S Soloway; Saleem A Umar; Theodorus H Van der Kwast
Journal:  Eur Urol       Date:  2012-10-12       Impact factor: 20.096

9.  Second opinion pathology in tertiary care of patients with urologic malignancies.

Authors:  Robert O Wayment; Andrew Bourne; Paul Kay; Thomas H Tarter
Journal:  Urol Oncol       Date:  2009-06-12       Impact factor: 3.498

10.  Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.

Authors:  Ashish M Kamat; Colin P N Dinney; Jason R Gee; H Barton Grossman; Arlene O Siefker-Radtke; Pheroze Tamboli; Michelle A Detry; Tracy L Robinson; Louis L Pisters
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

View more
  2 in total

1.  Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Authors:  Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

2.  MiR-192-5p suppresses the growth of bladder cancer cells via targeting Yin Yang 1.

Authors:  Decai Ji; Lining Jiang; Yingjie Li
Journal:  Hum Cell       Date:  2018-03-13       Impact factor: 4.174

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.